Mark White

Nexalin’s 2025 annual report states that Mark White earned a business management degree from the University of Houston.⁠[1]

He began building a portfolio of Houston service businesses, focusing on operating models and organizational management.⁠[2]

He shifted his business focus toward healthcare, particularly technologies related to mental health and addiction treatment.⁠[2]

His distribution business, iiCOM Strategic, became Nexalin Technology’s first national distributor.⁠[2]

He joined Nexalin’s corporate team, working on operations and business-model development. Its current biography describes his 2012–2018 role as an independent consultant.⁠[2][3]

Legacy Ventures International disclosed his appointment as interim CEO and interim CFO of both the parent and Nexalin, while retaining his COO responsibilities.⁠[4]

The same filing identified him as the founder of Houston’s Unique Mind Care and noted his experience operating clinics and addiction centers.⁠[4]

Nexalin’s current biography dates his tenure as president and CEO to 2018 and identifies him as a director. His responsibilities span medical-device development, clinical operations and business development.⁠[3]

Nexalin’s IPO comprised 2.315 million share-and-warrant units at $4.15 each, raising approximately $9.6 million before expenses. Its common stock began Nasdaq trading on September 16 under NXL.⁠[5]

School of Hard Knocks published his interview, 6 Questions With A Public CEO. Its description and chapters cover entrepreneurship, sales, business advice and mental health.⁠[6][7]

Nexalin disclosed a confidential settlement with Sarah Veltz, payment and dismissal. Her suit alleged unpaid wages and harassment by the CEO during her employment. The filing did not name that executive in this passage, so it does not establish allegations against White. The disclosure is not a judicial finding.⁠[1]

The company announced U.S. design patent D1,092,758 for its HALO Clarity transcranial electrostimulation device. White described its intended clinician-supervised home-use design. A design patent does not itself confer medical marketing authorization.⁠[8]

The company reported starting an FDA-cleared insomnia trial of its Gen-3 HALO device and recruiting participants. Product marketing authorization remained under pursuit.⁠[9]

Nexalin acquired all equity in PONM and related software-license rights to expand NeuroCare’s remote monitoring, physician workflow and clinical data capabilities.⁠[9]

Its half-year report disclosed recurring operating losses and negative operating cash flows, with management identifying substantial doubt about continued operations.⁠[9]

The company announced a ten-year exclusive distribution agreement with Inovanexa covering Brazil and six other countries, with an initial binding order for ten devices. White described it as a commercialization step. The announced 100-device framework did not represent 100 completed sales.⁠[10]

Nexalin announced restored compliance with Nasdaq’s minimum bid-price rule and conditional continued listing. It still had to meet the $2.5 million minimum stockholders’ equity requirement by January 4, 2027; the announcement did not resolve every listing condition.⁠[11]

In a School of Hard Knocks short interview, he advocated caution with debt and discussed financing ventures through personal or family resources. These were his business views.⁠[7]